top of page

Johnson & Johnson Bets $3.3 Billion on Experimental Eye Disease Treatment

34 minutes ago
2 min read

On November 16, 2026, Johnson & Johnson agreed upon a deal with Ollin Biosciences to acquire the company for a massive $3.3 billion. Johnson & Johnson is interested in Ollin’s treatments for eye diseases. However, this pipeline is still in an experimental phase and has yet to receive regulatory approval, signifying that J&J is taking a large risk with this investment. Regarding the deal itself, J&J will pay $2.2 billion upfront, while the remainder will arrive in payments dependent on future milestones. 


J&J is primarily targeting a drug called OLN324. OLN324 has the potential to be extremely successful and generate tons of revenue. The reason why is that the treatment targets two major eye diseases—wet age-related macular degeneration(wet AMD) and diabetic macular edema(DME). Patients with wet AMD suffer from impaired central vision because of the accumulation of abnormal blood vessels beneath the retina. Those with DME also experience impaired vision, but this damaged sight is caused by diabetes, which hurts the retinal blood vessels, leading to fluid accumulation in the macula. Together, these diseases affect roughly 40 million people worldwide. How OLN324 can treat these diseases is that it blocks two major protein pathways—VEGF and angiopoietin—that contribute to this abnormal blood vessel buildup and leakage. The treatment is currently undergoing Phase 3 clinical trials and has data from earlier phases that show promise for success. J&J therefore holds high hopes for the drug and its future success. 



There is another key player involved with this financial agreement. Blackstone Life Sciences has agreed to help J&J develop OLN324, providing $750 billion in exchange for eligibility to receive future payments tied to regulatory and sales milestones. This deal allows J&J to receive greater assistance to develop OLN324 through things like expensive clinical trials and to share some of the development risk with another company. Blackstone could have huge financial benefits if the drug succeeds but could also face disappointing returns if it fails. 


Looking towards the market that OLN324 sits within, the worldwide retinal therapeutics market is worth approximately $15 billion. Its current major competitors are Roche’s Vabysmo and Regeneron’s Eylea. J&J currently works in the eye care industry with products like contact lenses, surgical equipment, and medical devices. However, it has not yet had pharmaceutical treatments. Therefore, the acquisition of Ollin and the potential success of OLN324  would mean two things for J&J. First, it could capture a large portion of the lucrative retinal therapeutics market, providing another large source of revenue for the company. Second, J&J could break into the world of pharmaceutical treatments for retinal diseases.



Ultimately, J&J’s multibillion-dollar acquisition of Ollin represents a major bet on the future of retinal disease treatments. While OLN324 has the potential to generate substantial revenue and expand J&J’s pharmaceutical portfolio, its success will ultimately depend on whether the drug can gain regulatory approval and compete with established treatments.









 
 
bottom of page